Consun Pharmaceutical Group Limited (Consun Pharma) disclosed that it repurchased 112,000 ordinary shares on 4 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices between HKD 14.02 and HKD 14.22 per share, for a total consideration of HKD 1.58 million, implying a volume-weighted average cost of HKD 14.13 per share.

Following the transaction, Consun Pharma’s outstanding share count (excluding treasury shares) declined by 0.0133% to 840.65 million shares, while treasury shares rose from 789,000 to 901,000. The company’s total issued share capital, including treasury shares, remains unchanged at 841.55 million shares.

The repurchase forms part of the mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. To date, Consun Pharma has repurchased 557,000 shares under this mandate, equivalent to 0.6621% of the issued share base on the mandate date.

In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 July 2026.